SITE SELECTION AND ASSESSMENT

Our multifaceted approach to site identification and selection is tailored to each study protocol to ensure the best-fit sites with the most appropriate capabilities and population.

Our relationships with sites are built on our shared investment in their sustainability, helping sites develop and maintain research capacity so they are research-ready as soon as there is a need. Ultimately, this increased research capacity will help address public health issues around the globe.

Benefits of Collaboration

Learn more about our specific experience through our case studies:

Case Study
Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Rapid Site Assessment and Recommendations for Clinical Trials of a New Malaria Treatment

Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
Case Study
Phase II Trial of a Chikungunya Vaccine in the Caribbean

Phase II Trial of a Chikungunya Vaccine in the Caribbean

The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Case Study
Rescue of an Ongoing Global, Multi-Site Oncology Trial

Rescue of an Ongoing Global, Multi-Site Oncology Trial

In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.